Qualigen Therapeutics, Inc.
NASDAQ: QLGN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kevin A. Richardson II
- Employees
- 4
- Headquarters
- Carlsbad, United States
- IPO year
- 2015
- Market cap
- $5.4M
- Website
- https://qlgntx.com
Loading QLGN…
Loading profile data…Frequently asked questions about QLGN
What does Qualigen Therapeutics, Inc. (QLGN) do?
Qualigen Therapeutics, Inc. is a biotechnology enterprise focused on advancing groundbreaking treatments for both cancer and infectious diseases. In addition to its developmental pipeline, the company offers FastPack, an efficient system designed for swift diagnostic testing. Its therapeutic candidates currently undergoing development include QN...
Where does QLGN trade?
Qualigen Therapeutics, Inc. (QLGN) trades on the NASDAQ Capital Market.
What sector is QLGN in?
Qualigen Therapeutics, Inc. (QLGN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Qualigen Therapeutics, Inc.?
Kevin A. Richardson II is the chief executive officer of Qualigen Therapeutics, Inc. (QLGN).
Where is Qualigen Therapeutics, Inc. headquartered?
Qualigen Therapeutics, Inc. is headquartered in United States.
Does QLGN pay a dividend?
Qualigen Therapeutics, Inc. (QLGN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did QLGN go public?
Qualigen Therapeutics, Inc. (QLGN) completed its initial public offering in 2015.